Last reviewed · How we verify
NCT05797298
Toric Intraocular Lens (IOL) Implantation for Management of Cataracts
trial in Toric Intraocular Lens Stability in 3,000 participants. Currently enrolling.
31 March 2030
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 June 2019 |
| Primary completion | 31 March 2030 |
| Estimated completion | 31 May 2030 |
| Sites | 2 locations across China |
Conditions studied
- Toric Intraocular Lens Stability — all drugs for Toric Intraocular Lens Stability →
- Visual Quality — all drugs for Visual Quality →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
Eligibility, any sex, with Toric Intraocular Lens Stability or Visual Quality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study included cataract patients who underwent toric intraocular lens (IOL) implantation, which aimed to evaluate the stability and clinical visual quality of toric IOLs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nomogram for predicting significant rotation after plate-haptic toric intraocular lens implantation in a Chinese population.
Lin X, Hua Z, Shen W, Zhuo B, et al · · 2026 · PMID 41521484 · DOI 10.1097/j.jcrs.0000000000001874
Verify or expand the search:
- PubMed search for NCT05797298
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05797298 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: 19 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05797298.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing